EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study
Carolina Martínez‐Laperche, Pilar Lancho‐Lavilla, Antonio Gutiérrez, Antonio Salar, Javier López‐Jiménez, Blanca Ferrer‐Lores, Alicia Serrano, Ana Jiménez‐Ubieto, María Poza, Francisco Javier Díaz‐Crespo, Paula Fernández‐Caldas, Laura Sanz‐Villanueva, Javier Menárguez‐Palanca, Ismael Buño, María Gar · 2026
Read EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study by Carolina Martínez‐Laperche, Pilar Lancho‐Lavilla, Antonio Gutiérrez, Antonio Salar, Javier López‐Jiménez, Blanca Ferrer‐Lores, Alicia Serrano, Ana Jiménez‐Ubieto, María Poza, Francisco Javier Díaz‐Crespo, Paula Fernández‐Caldas, Laura Sanz‐Villanueva, Javier Menárguez‐Palanca, Ismael Buño, María Gar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13671356.txt.
Description
Carolina Martínez-Laperche and colleagues tested in 2026 whether a single gene mutation predicts which follicular lymphoma patients fare badly on a common first treatment. Follicular lymphoma is the most common slow-growing lymphoma, and bendamustine-based immunochemotherapy is a standard frontline regimen. Mutations in the EZH2 gene are part of its genetic landscape. The Spanish GELTAMO group ran a multicenter validation study to check earlier hints that EZH2 status matters.
Their title states the conclusion plainly: patients whose tumors carry EZH2 mutations had inferior outcomes after bendamustine-based therapy. A validation study of this kind matters because a marker only helps clinics if it holds up across many hospitals and patient groups. If confirmed in practice, EZH2 testing could flag patients who need a different first regimen or closer watching, instead of discovering the poor response only when the disease returns.
Catalog record
| CREATOR | Carolina Martínez‐Laperche, Pilar Lancho‐Lavilla, Antonio Gutiérrez, Antonio Salar, Javier López‐Jiménez, Blanca Ferrer‐Lores, Alicia Serrano, Ana Jiménez‐Ubieto, María Poza, Francisco Javier Díaz‐Crespo, Paula Fernández‐Caldas, Laura Sanz‐Villanueva, Javier Menárguez‐Palanca, Ismael Buño, María Gar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |